AllianceBernstein’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

AllianceBernstein’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-152	Closed	-$188K	–	3355
2022 Q1	$188K	Hold	152	–	–	﹤0.01%	3005
2021 Q4	$384K	Hold	152	–	–	﹤0.01%	2847
2021 Q3	$2.79M	Hold	152	–	–	﹤0.01%	1961
2021 Q2	$1.61M	Buy	152 +98	+181%	+$822K	﹤0.01%	2307
2021 Q1	$389K	Sell	54 -32	-37%	-$230K	﹤0.01%	2786
2020 Q4	$478K	Sell	86 -11	-11%	-$97.5K	﹤0.01%	2618
2020 Q3	$970K	Sell	97 -3	-3%	-$27.3K	﹤0.01%	2200
2020 Q2	$926K	Buy	100 +26	+35%	+$238K	﹤0.01%	2244
2020 Q1	$670K	Sell	74 -4	-5%	-$39.5K	﹤0.01%	2218
2019 Q4	$876K	Buy	78 +32	+70%	+$193K	﹤0.01%	2331
2019 Q3	$229K	Buy	+46	New	+$283K	﹤0.01%	2897

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

AllianceBernstein's IRLA Position: Q2 2022 in Review

AllianceBernstein sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2022, closing a stake of 152 shares — an estimated $188K sold.

AllianceBernstein first reported a position in IRLA in Q3 2019 and held it in 11 quarters. The position peaked at $2.79M in Q3 2021. 66 funds tracked by Wall St. Rank hold IRLA as of Q2 2022.

AllianceBernstein reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
AllianceBernstein sold 152 IRulya Therapeutics Inc. Common Stock shares in Q2 2022, an estimated $188K.
AllianceBernstein first reported a position in IRulya Therapeutics Inc. Common Stock in Q3 2019 and held it in 11 quarters.
AllianceBernstein's IRulya Therapeutics Inc. Common Stock position peaked at $2.79M in Q3 2021.
66 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2022.

Based on AllianceBernstein's 13F filing for Q2 2022, filed 15 Aug 2022.